IQVIA Holdings Inc. (LON:0JDM)
246.81
+5.79 (2.40%)
At close: Jan 9, 2026
IQVIA Holdings Revenue
IQVIA Holdings had revenue of $4.10B USD in the quarter ending September 30, 2025, with 5.24% growth. This brings the company's revenue in the last twelve months to $15.90B, up 3.85% year-over-year. In the year 2024, IQVIA Holdings had annual revenue of $15.41B with 2.81% growth.
Revenue (ttm)
$15.90B
Revenue Growth
+3.85%
P/S Ratio
2.60
Revenue / Employee
$180.73K
Employees
88,000
Market Cap
30.79B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.41B | 421.00M | 2.81% |
| Dec 31, 2023 | 14.98B | 574.00M | 3.98% |
| Dec 31, 2022 | 14.41B | 536.00M | 3.86% |
| Dec 31, 2021 | 13.87B | 2.52B | 22.14% |
| Dec 31, 2020 | 11.36B | 271.00M | 2.44% |
| Dec 31, 2019 | 11.09B | 676.00M | 6.49% |
| Dec 31, 2018 | 10.41B | 710.00M | 7.32% |
| Dec 31, 2017 | 9.70B | 2.89B | 42.36% |
| Dec 31, 2016 | 6.82B | 1.08B | 18.79% |
| Dec 31, 2015 | 5.74B | 277.00M | 5.07% |
| Dec 31, 2014 | 5.46B | 360.46M | 7.07% |
| Dec 31, 2013 | 5.10B | 234.03M | 4.81% |
| Dec 31, 2012 | 4.87B | 537.77M | 12.43% |
| Dec 31, 2011 | 4.33B | 403.73M | 10.29% |
| Dec 31, 2010 | 3.92B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
IQVIA Holdings News
- 2 days ago - IQV: Truist Securities Maintains 'Buy' Rating, Raises Price Target to $290 | IQV Stock News - GuruFocus
- 2 days ago - IQV: UBS Raises Price Target to $280, Maintains Buy Rating | IQV Stock News - GuruFocus
- 12 days ago - Here's Why You Should Retain IQV Stock in Your Portfolio Now - Nasdaq
- 22 days ago - Harbor Mid Cap Core ETF Q3 2025 Portfolio Review - Seeking Alpha
- 4 weeks ago - IQVIA: Increasingly Indispensable In Drug Development - Seeking Alpha
- 4 weeks ago - IQVIA Holdings Inc. (IQV) Announces Amendment to Credit Agreement - GuruFocus
- 5 weeks ago - IQV Quantitative Stock Analysis - Nasdaq
- 5 weeks ago - IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform - Business Wire